Zimmer Biomet Holdings, a major manufacturer of musculoskeletal devices, will buy spinal device company LDR Holding Corp. for $1 billion.
Physicians have increasingly looked to 3-D printing for unique implants and surgical models, and some manufacturers are now using the method to mass produce medical devices and even drugs that are more precise, customizable and biocompatible than conventionally produced products.
Federal prosecutors say a drug and medical device manufacturer has agreed to pay up to $7.8 million for selling contaminated syringes.
Four major health systems have joined forces with two environmental organizations to launch a purchasing cooperative focused on “green” products that could compete with traditional group purchasing organizations.
McKesson Corp. announced two deals with big-box chain Wal-Mart Stores that are expected to boost the healthcare giant after recent struggles.
Hospitals—having spent the better part of the past decade working with their surgeons to narrow the variety of cardiovascular, orthopedic and other implants used in their operating rooms—are now looking for new ways to cut expenses related to these high-cost items.
Executives at AmerisourceBergen Corp. are concerned about the company's future, even though revenue growth was moderately positive this quarter.
Owens & Minor reported a notable increase in first-quarter earnings, allowing the company to beat analyst expectations despite the impending loss of of a major customer.
Cardinal Health reported a bump in revenue in its third quarter, driven by gains in the company's pharmaceutical segment. The Dublin, Ohio-based drug and medical products distributor reported $386 million in earnings during the last quarter, up 6% from last year.
Kaiser Permanente has dropped its $525 million contract with Owens & Minor for medical-surgical supply distribution, marking the second time that the supplier has reported a major contract loss in less than a year.
The FDA issued draft guidance last week that clarifies the amount of drugs that providers can compound without a prescription, sets requirements for health system compounding pharmacies and clarifies how large-scale compounding sites known as “outsourcing facilities” may be set up.
The proposed rules clarify the amount of drugs that providers can compound without a prescription, set requirements for health system compounding pharmacies and clarify how large-scale compounding sites known as “outsourcing facilities” may be set up.